The Role of MiRNAs in the Diagnosis, Chemoresistance, and Prognosis of Pancreatic Ductal Adenocarcinoma

Overview

Journal Ther Clin Risk Manag

Publisher Dove Medical Press

Date 2018 Feb 9

PMID 29416345

Citations 8

Authors

Le Ren

Yue Yu

Affiliations

Soon will be listed here.

Abstract

Pancreatic ductal adenocarcinoma (PDAC) remains a very challenging malignancy with late presentation, metastatic potential, chemoresistance, and poor prognosis. Therefore, there is an urgent need for novel diagnostic and prognostic biomarkers. miRNAs are small noncoding RNAs that regulate the expression of multitude number of genes. Aberrant expression of miRNAs has been linked to the development of various malignancies, including PDAC. A series of miRNAs have been defined as holding promise for early diagnostics, as indicators of therapy resistance, and even as markers for prognosis in PDAC patients. In this review, we summarize the current knowledge on the role of miRNAs in diagnosis, chemoresistance, and prognosis in PDAC patients.

Citing Articles

Extracellular Vesicular miRNA in Pancreatic Cancer: From Lab to Therapy.

Tiwari P, Shanmugam P, Karn V, Gupta S, Mishra R, Rustagi S Cancers (Basel). 2024; 16(12).

PMID: 38927885 PMC: 11201547. DOI: 10.3390/cancers16122179.

(hsa_circ_0000919) promotes cell proliferation and metastasis and inhibits cell apoptosis in pancreatic ductal adenocarcinoma via the axis: implications for novel therapeutic targets.

Wangpu X, Zhao J, Yu C, Yu S, Wang H, Yuan Z Am J Cancer Res. 2023; 13(11):5610-5625.

PMID: 38058810 PMC: 10695776.

Evaluation of Serum microRNA Let-7c and Let-7d as Predictive Biomarkers for Metastatic Pancreatic Cancer.

Demiray A, Demiray A, Yaren A, Taskoylu B, Dogu G, Degirmencioglu S Turk J Gastroenterol. 2022; 33(8):696-703.

PMID: 35943151 PMC: 9524463. DOI: 10.5152/tjg.2022.21829.

Tumour suppressor microRNAs contribute to drug resistance in malignant pleural mesothelioma by targeting anti-apoptotic pathways.

Williams M, Cheng Y, Phimmachanh M, Winata P, van Zandwijk N, Reid G Cancer Drug Resist. 2022; 2(4):1193-1206.

PMID: 35582270 PMC: 9019216. DOI: 10.20517/cdr.2019.41.

Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels.

Panebianco C, Trivieri N, Villani A, Terracciano F, Latiano T, Potenza A Biomolecules. 2021; 11(5).

PMID: 33925948 PMC: 8146031. DOI: 10.3390/biom11050639.

References

Zhang L, Yao J, Li W, Zhang C . Micro-RNA-21 Regulates Cancer-Associated Fibroblast-Mediated Drug Resistance in Pancreatic Cancer. Oncol Res. 2017; 26(6):827-835. PMC: 7844724. DOI: 10.3727/096504017X14934840662335. View

Fan P, Liu L, Yin Y, Zhao Z, Zhang Y, Amponsah P . MicroRNA-101-3p reverses gemcitabine resistance by inhibition of ribonucleotide reductase M1 in pancreatic cancer. Cancer Lett. 2016; 373(1):130-137. DOI: 10.1016/j.canlet.2016.01.038. View

Li Y, VandenBoom 2nd T, Kong D, Wang Z, Ali S, Philip P . Up-regulation of miR-200 and let-7 by natural agents leads to the reversal of epithelial-to-mesenchymal transition in gemcitabine-resistant pancreatic cancer cells. Cancer Res. 2009; 69(16):6704-12. PMC: 2727571. DOI: 10.1158/0008-5472.CAN-09-1298. View

Wei X, Wang W, Wang L, Zhang Y, Zhang X, Chen M . MicroRNA-21 induces 5-fluorouracil resistance in human pancreatic cancer cells by regulating PTEN and PDCD4. Cancer Med. 2016; 5(4):693-702. PMC: 4831288. DOI: 10.1002/cam4.626. View

Nagano H, Tomimaru Y, Eguchi H, Hama N, Wada H, Kawamoto K . MicroRNA-29a induces resistance to gemcitabine through the Wnt/β-catenin signaling pathway in pancreatic cancer cells. Int J Oncol. 2013; 43(4):1066-72. DOI: 10.3892/ijo.2013.2037. View

Ikenaga N, Ohuchida K, Mizumoto K, Yu J, Kayashima T, Sakai H . MicroRNA-203 expression as a new prognostic marker of pancreatic adenocarcinoma. Ann Surg Oncol. 2010; 17(12):3120-8. DOI: 10.1245/s10434-010-1188-8. View

Zhou G, Liu X, Wang X, Jin D, Chen Y, Li G . Combination of preoperative CEA and CA19-9 improves prediction outcomes in patients with resectable pancreatic adenocarcinoma: results from a large follow-up cohort. Onco Targets Ther. 2017; 10:1199-1206. PMC: 5338972. DOI: 10.2147/OTT.S116136. View

Long L, Zhan J, Wang H, Li S, Chen Y, Liu Y . The Clinical Significance of miR-34a in Pancreatic Ductal Carcinoma and Associated Molecular and Cellular Mechanisms. Pathobiology. 2016; 84(1):38-48. DOI: 10.1159/000447302. View

Zhang S, Hao J, Xie F, Hu X, Liu C, Tong J . Downregulation of miR-132 by promoter methylation contributes to pancreatic cancer development. Carcinogenesis. 2011; 32(8):1183-9. DOI: 10.1093/carcin/bgr105. View

10.

Komatsu S, Ichikawa D, Takeshita H, Morimura R, Hirajima S, Tsujiura M . Circulating miR-18a: a sensitive cancer screening biomarker in human cancer. In Vivo. 2014; 28(3):293-7. View

11.

Hanoun N, Delpu Y, Suriawinata A, Bournet B, Bureau C, Selves J . The silencing of microRNA 148a production by DNA hypermethylation is an early event in pancreatic carcinogenesis. Clin Chem. 2010; 56(7):1107-18. DOI: 10.1373/clinchem.2010.144709. View

12.

Li B, Liu H, Yang W . Reduced miRNA-218 expression in pancreatic cancer patients as a predictor of poor prognosis. Genet Mol Res. 2015; 14(4):16372-8. DOI: 10.4238/2015.December.9.5. View

13.

Park J, Lee E, Esau C, Schmittgen T . Antisense inhibition of microRNA-21 or -221 arrests cell cycle, induces apoptosis, and sensitizes the effects of gemcitabine in pancreatic adenocarcinoma. Pancreas. 2009; 38(7):e190-9. DOI: 10.1097/MPA.0b013e3181ba82e1. View

14.

Park J, Henry J, Jiang J, Esau C, Gusev Y, Lerner M . miR-132 and miR-212 are increased in pancreatic cancer and target the retinoblastoma tumor suppressor. Biochem Biophys Res Commun. 2011; 406(4):518-23. PMC: 3069485. DOI: 10.1016/j.bbrc.2011.02.065. View

15.

Costello E, Greenhalf W, Neoptolemos J . New biomarkers and targets in pancreatic cancer and their application to treatment. Nat Rev Gastroenterol Hepatol. 2012; 9(8):435-44. DOI: 10.1038/nrgastro.2012.119. View

16.

Kim J, Bamlet W, Oberg A, Chaffee K, Donahue G, Cao X . Detection of early pancreatic ductal adenocarcinoma with thrombospondin-2 and CA19-9 blood markers. Sci Transl Med. 2017; 9(398). PMC: 5727893. DOI: 10.1126/scitranslmed.aah5583. View

17.

Bloomston M, Frankel W, Petrocca F, Volinia S, Alder H, Hagan J . MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007; 297(17):1901-8. DOI: 10.1001/jama.297.17.1901. View

18.

Li M, Marin-Muller C, Bharadwaj U, Chow K, Yao Q, Chen C . MicroRNAs: control and loss of control in human physiology and disease. World J Surg. 2008; 33(4):667-84. PMC: 2933043. DOI: 10.1007/s00268-008-9836-x. View

19.

Ren Y, Gao J, Liu J, Wang X, Gu J, Huang H . Differential signature of fecal microRNAs in patients with pancreatic cancer. Mol Med Rep. 2012; 6(1):201-9. DOI: 10.3892/mmr.2012.862. View

20.

Hwang J, Voortman J, Giovannetti E, Steinberg S, Leon L, Kim Y . Identification of microRNA-21 as a biomarker for chemoresistance and clinical outcome following adjuvant therapy in resectable pancreatic cancer. PLoS One. 2010; 5(5):e10630. PMC: 2871055. DOI: 10.1371/journal.pone.0010630. View